Detail akcie EyePoint Pharmaceuticals, Inc online

Business Summary: EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Eyepoint Pharmaceuticals Inc revenues decreased 3% to $30.8M. Net loss increased 84% to $164.4M. Revenues reflect License and collaboration agreements decrease of 41% to $16.5M, Revenue decrease of 46% to $1.3M. Higher net loss reflects Research and Development Expense increase of 43% to $104.9M (expense), Interest and other income decrease of 21% to $8.8M (income).